Federal funding allowed Corning to expand the high-volume manufacturing facility, fortifying industry in North Carolina and supporting the United States’ global vaccination efforts.
One glass vial can store multiple doses of a life-saving vaccine. With an expansion in Durham, North Carolina, Corning's high-volume manufacturing facility can produce up to 500 million vials, which can store nearly 4.3 billion doses annually and aid the progress of public health.
Corning has helped combat COVID-19, ramping up production of its damage-resistant Valor® Glass vials and enabling delivery of over 3 billion doses of COVID-19 vaccines in the past 20 months. Along with Valor Glass, the Durham facility will manufacture Corning's new Velocity® Vials, Corning Pharmaceutical Technologies' recently announced innovative technology that directly responds to pharmaceutical supply-chain challenges. The coated borosilicate vials are engineered to improve drug quality and increase pharmaceutical filling line efficiency, compared to conventional borosilicate vials.
Approximately $261 million of federal funding from the Biomedical Advanced Research and Development Authority (BARDA) allowed Corning to expand production at Durham and two other Life Sciences facilities. BARDA, a U.S. Department of Health and Human Services office, works with industry partners to secure the development of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies.